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1607-551X/Copyright ª 2014, KaohsiuAbstract The management of acute cholecystitis is still based on clinical expertise. This
study aims to investigate whether the outcome of acute cholecystitis can be related to
the severity criteria of the Tokyo guidelines and additional clinical comorbidities. A total
of 103 patients with acute cholecystitis were retrospectively enrolled and their medical
records were reviewed. They were all classified according to therapeutic modality,
including early cholecystectomy and antibiotic treatment with or without percutaneous
cholecystostomy. The impact of the Tokyo guidelines and the presence of comorbidities
on clinical outcome were assessed by univariate and multivariate regression analyses. Ac-
cording to Tokyo severity grading, 48 patients were Grade I, 31 patients were Grade II,
and 24 patients were Grade III. The Grade III patients had a longer hospital stay than
Grade II and Grade I patients (15.2 days, 9.2 days, and 7.3 days, respectively,
p < 0.05). According to multivariate analysis, patients with Grade III Tokyo severity, high-
er Charlson’s Comorbidity Score, and encountering complications had a longer hospital
stay. Based on treatment modality, surgeons selected the patients with less severity
and fewer comorbidities for cholecystectomy, and these patients had a shorter hospitaleclare no conflicts of interest.
of Internal Medicine, National Cheng Kung University Hospital, Number 138 Sheng-Li Road, Tainan
ku.edu.tw (C.-Y. Chen).
4.05.005
ng Medical University. Published by Elsevier Taiwan LLC. All rights reserved.
460 W.-C. Cheng et al.stay. In addition to the grading of the Tokyo guidelines, comorbidities had an additional
impact on clinical outcomes and should be an important consideration when making ther-
apeutic decisions.
Copyright ª 2014, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Cholecystitis is defined as inflammation of the gallbladder
that occurs most commonly because of an obstruction of
the cystic duct from gallstones [1,2]. Cholecystectomy,
preferably laparoscopic cholecystectomy, is the standard
treatment for acute cholecystitis. However, in patients who
are not suited to early surgery, conservative treatment such
as parenteral antibiotics or percutaneous cholecystostomy
is recommended.
The Tokyo guidelines for the management of acute
cholangitis and cholecystitis were published in 2006 and
revised in 2012 to provide clinical guidelines for the diag-
nosis and treatment of acute cholecystitis [3,4]. The
guidelines recommend that patients with mild cholecystitis
(Grade I) should undergo early laparoscopic cholecystec-
tomy, whereas patients with severe cholecystitis (Grade III)
should receive initial antibiotic treatment with or without
percutaneous cholecystostomy. For moderate cholecystitis
(Grade II), the management is usually dependent on the
expertise of the surgeon. Lee at al [5] retrospectively
reviewed their chart records and found that the mean
length of hospital stay was less when the clinical decisions
were compliant to the guidelines.
In clinical practice, in addition to disease severity, the
medical background and comorbidity of patients are also
important factors to be considered when deciding on the
treatment modality. Tokyo guidelines focused only on signs
of inflammation and systemic complications, while over-
looking the conditions of the patients. We therefore
retrospectively assessed if the patients’ comorbidities, as
well as the Tokyo grading, affected the treatment decisions
and outcomes of our patients with acute calculous
cholecystitis.Materials and methods
Patients
Prior to when data collection was conducted, approval was
obtained from the Institutional Review Board of the Na-
tional Cheng Kung University Hospital, a tertiary referral
medical center in Southern Taiwan. Using the International
Classification of Diseases, ninth revision (ICD-9) codes, pa-
tients admitted to our hospital with a diagnosis of acute
cholecystitis between January 2005 and February 2007
were identified retrospectively. The patients were diag-
nosed based on typical physical findings, systemic inflam-
mation signs, and abdominal imaging (abdominal
ultrasonography and/or computed tomography). Forpatients who had an uncertain diagnosis with regards to
acute cholecystitis, the diagnosis was confirmed by either
pathology in patients who had undergone surgery, or with
the finding of dirty bile in patients who had undergone
cholecystostomy. The exclusion criteria were patients with
acute acalculous cholecystitis, co-existing malignancy,
concomitant cholangitis or pancreatitis, chronic cholecys-
titis, and those younger than 18 years of age. Patients who
received more than one intervention (i.e., cholecystostomy
and surgery during the same admission) were also excluded,
as we were unable to eliminate the impact of chol-
ecystostomy on the surgical outcomes which may further
complicate analysis.
Data collected from the medical records included
age, sex, duration of symptoms, specific disease en-
tities, presenting vital signs, weight, height, physical
findings, and laboratory data. In addition, the diag-
nostic criteria of the Tokyo guidelines including right
upper quadrant (RUQ) pain, Murphy’s sign (tenderness
elicited by placing a hand below the right costal margin
and asking the patient to inspire, or by directly placing
a sonography probe on the gallbladder on sonography
examination), fever (body temperature > 38.3C),
raised C-reactive protein (CRP) > 3 mg/dL, elevated
white blood cell (WBC) count higher than the upper
limit of normal, gall bladder wall thickening > 3 mm,
gall bladder enlargement (>8 cm in long axis or 4 cm in
short axis), pericholecystic fluid accumulation, and
striated intramural lucency shown on sonography or
computed tomography imaging were recorded. The
severity of the patients was graded according to the
Tokyo guidelines (Table 1) [4]. In addition, the Charl-
son’s Comorbidity Score (without adding the age score)
was also calculated to evaluate the impact of each
patient’s comorbidity on the clinical outcomes [6].
Strategy of management
In our hospital, surgeons were consulted first for patients
with acute cholecystitis. The decision to perform chole-
cystectomy was made according to the expertise of the
surgeons (in total, 8 surgeons were responsible for decision
making) and also patient preference. Patients who did not
undergo cholecystectomy were treated with antibiotic
therapy alone or antibiotic therapy plus percutaneous
cholecystostomy. The decision to perform percutaneous
cholecystostomy was made if the patient had persistent
fever, severe pain, dyspnea, unstable hemodynamics, or
consciousness disturbance despite the use of antibiotics.
Usually in our hospital, patients who did not undergo sur-
gery as the first treatment were discharged after their
Table 1 Severity grading according to the Tokyo guidelines for acute cholecystitis [4].
Grade Criteria
I Mild Acute cholecystitis not meeting other severity criteria
Mild gallbladder inflammation, no organ dysfunction
II Moderate Acute cholecystitis with any of following conditions:
 Elevated WBC count (>18,000/mL)
 Palpable tender mass at right upper quadrant
 Duration of complaints > 72 h
 Marked local inflammation, such as biliary peritonitis, pericholecystic abscess,
hepatic abscess, gangrenous cholecystitis, emphysematous cholecystitis
III Severe Acute cholecystitis accompanied with organ dysfunction:
 Cardiovascular dysfunction (hypotension requiring treatment with dopamine
at >5 mg/kg body weight/min or any dose of norepinephrine)
 Neurological dysfunction (decreased level of consciousness)
 Respiratory dysfunction (PaO2/FiO2 < 300)
 Renal dysfunction (oliguria, creatinine > 2.0 mg/dL)
 Hepatic dysfunction (PT-INR > 1.5)
 Hematologic dysfunction (platelet count < 100,000/mL)
PT-INR Z prothrombin time-international normalized ratio; WBC Z white blood cell.
Clinical outcomes of acute cholecystitis 461clinical conditions became more stable. However, there
was no rigid protocol and some patients may have under-
gone surgery a couple of days after receiving medical
treatment or cholecystostomy due to patient or physician
preferences.
Outcome variables included the length of hospital stay,
complications associated with procedures, and mortality.
For recording complications, we applied the classification
proposed by Dindo et al. [7], and only major complications
more severe than Grade II (requiring further interventions,
life threatening, or resulting in mortality) were recorded as
positive.Figure 1. The flow charStatistical analysis
Predictive Analytics SoftWare (PAWS) version 17 (IBM, Chi-
cago, IL, USA) and R version 3.0.0 (http://www.R-project.
org) were used for statistical analysis. The clinical charac-
teristics and outcomes of the patients among different
subgroups were analyzed with the Student t test or one way
analysis of variance (ANOVA) with Tukey’s honestly signifi-
cant difference test as post hoc analysis. The categorical
data among the different severity groups were analyzed
using Pearson’s Chi-square test. Univariate linear regression
analysis was carried out to identify the factors associatedt of patient inclusion.
462 W.-C. Cheng et al.with regards to length of hospital stay. All variables with an
effect on hospital stay (p  0.2) were entered into a
multivariate linear regression model. A p value of <0.05
was considered to be statistically significant.Results
From January 2005 to February 2007, a total of 179 patients
were diagnosed with acute cholecystitis and were admitted
to our hospital. As shown in Fig. 1, 76 patients were
excluded and a final total of 103 patients were included for
this study. In these patients, 36 patients received direct
cholecystectomy, 40 patients received cholecystostomy,
and the remaining 27 patients were treated by antibiotics
only. In the 36 patients who received cholecystectomy, 23
received laparoscopic cholecystectomy and 13 receivedTable 2 Clinical characteristics of the patients by
different Tokyo guidelines severity grade.
Patient number Grade I Grade II Grade III
Mild Moderate Severe
48 31 24
Age (y) 60.3  15.0 63.6  16.4 67.2  12.1
Male/female 29/19 20/11 11/13
Body mass index 25.1  3.7 25.5  3.8 24.9  5.0
Diagnostic criteriaa 37 (77.1) 22 (71.0) 15 (62.5)
Murphy’s sign 19 (39.6) 12 (38.7) 11 (45.8)
RUQ pan 37 (77.1) 21 (67.7) 16 (66.7)
Fever 30 (62.5) 26 (83.9) 19 (79.2)
Elevated CRP* 27 (56.3) 28 (90.3) 19 (79.2)
Elevated WBC 37 (77.1) 27 (87.1) 18 (75.0)
Image 41 (93.2) 28 (100) 19 (100)















Local complication* 0 (0) 6 (19.4) 0 (0)
Onset > 72 hours* 0 (0) 11 (35.5) 2 (8.3)
RUQ tender mass 0 (0) 0 (0) 0 (0)
WBC > 18,000/mL* 0 (0) 18 (58.1) 5 (20.8)
Cardiovascular
dysfunction*
0 (0) 0 (0) 5 (20.8)
Neurologic
dysfunction
0 (0) 0 (0) 1 (4.2)
Pulmonary
dysfunction*
0 (0) 0 (0) 3 (12.5)
Renal dysfunction* 0 (0) 0 (0) 9 (37.5)
Hepatic dysfunction* 0 (0) 0 (0) 4 (16.7)
Hematologic
dysfunction*
0 (0) 0 (0) 8 (33.3)
Data are presented as n (%) or mean  SD, unless otherwise
indicated.
*p < 0.05 by Pearson’s Chi-square test.
BMIZ body mass index; CRPZ C-reactive protein; RUQZ right
upper quadrant; WBC Z white blood cell.
a Patient that fulfilled the diagnostic criteria of the Tokyo
guidelines.open cholecystectomy. The open cholecystectomy patients
were older than the laparoscopic cholecystectomy patients
(66.4  11.2 years old vs. 54.7  16.4 years old, pZ 0.029),
but there were no statistically significant differences in the
length of hospital stay and other clinical parameters be-
tween the two groups (data not shown); therefore, they
were analyzed together as the surgery group.
The demographic data and clinical characteristics of the
patients are shown in Table 2. A total of 74 patients (71.8%)
fulfilled the diagnostic criteria of the Tokyo guidelines. The
Grade II severity group had the highest percentage of pa-
tients with raised CRP and local complications on imaging.
The patients were classified as Grade II mostly because of
leukocytosis on presentation (WBC > 18,000/mL) or having
had symptoms for more than 72 hours. The most frequently
seen systemic complications of acute cholecystitis causing
patients to be classified as Grade III were kidney and he-
matology dysfunction.
As shown in Table 3, our surgeons selected the least
number of patients for cholecystectomy from the Grade III
group (2 out of 24 patients, 8.3%), and most of the
remaining patients in the Grade III group underwent
percutaneous cholecystostomy (18 patients, 75.0%). The
length of hospital stay of the Grade III group was signifi-
cantly longer than that of the other groups. Regarding the
impact of treatment on hospital stay, the hospital stay was
similar between Grade I patients who received surgery or
non-surgical management (6.8  3.0 days vs. 7.6  3.8
days, p Z 0.491). However, regardless of the severity
grading, the patients who underwent percutaneous chol-
ecystostomy had a longer hospital stay than those who
received antibiotic treatment or surgery.
In total, 19 patients (25.0% of 76 cases who received
intervention) encountered major complications during
hospitalization (Table 4). The complication rate increased
along with Tokyo grading (Grade I: 3/31, 9.7%, Grade II: 7/
25, 28.0%, Grade III: 9/20, 45.0%, pZ 0.016). Furthermore,
patients who underwent cholecystostomy had a higher
complication rate than those who received surgery (35.0%
vs. 13.9%, pZ 0.034). Of the 14 patients who encountered
complications of cholecystostomy, nine patients were of
Tokyo Grade III. The mortality rate was not high in our
study, with both two cases (1.9%) being Tokyo Grade III.
The clinical characteristics of patients who received
surgery or non-surgical treatment are shown in Table 5.
Patients who did not undergo cholecystectomy were older,
had higher rates of raised serum CRP or leukocytosis, more
organ dysfunctions, and more comorbidities as indicated by
higher Charlson’s Comorbidity Score than patients who
underwent surgical treatment.
A linear regression model was used to eliminate the
confounding variables caused by nonrandomized treatment
assignment and to evaluate factors that were possibly
associated with hospital stay. As shown in Table 6,
increased age, severity Grade III (compared to Grade I),
increased heart rate on presentation, higher Charlson’s
Comorbidity Score, patients who received cholecystostomy,
and encountering complications were factors associated
with increased length of hospital stay. However, in multi-
variate analysis, only Tokyo severity Grade III, increased
Charlson’s Comorbidity Score, and encountering complica-
tions remained significant.
Table 3 Hospital stay according to Tokyo grading and treatment modality.
Antibiotics Cholecystostomy Surgery Total
Tokyo Grade I 6.9  3.9 (17) 8.4  3.8 (13) 6.8  3.0 (18) 7.3  3.5 (48)*
Tokyo Grade II 7.8  2.6 (6) 9.8  3.8 (9) 9.4  4.5 (16) 9.2  3.9 (31)*
Tokyo Grade III 7.3  4.1 (4) 17.4  8.5 (18) 11.0  4.2 (2) 15.2  8.5 (24)*
Total 7.2  3.6 (27)* 12.9  7.6 (40)* 8.1  3.9 (36)* 9.7  6.0 (103)
Data are presented as mean days  standard deviation, with case numbers in parentheses.
*p < 0.05 by analysis of variance.
Table 5 The significantly different characteristics be-






Age (y)** 65.1  14.3 58.9  15.7 0.044
Sex (male, %) 36 (53.7) 24 (66.7) 0.218
BMI 25.2  4.4 25.1  3.3 0.876
RUQ pain* 43 (64.2) 31 (86.1) 0.018
Elevated CRP* 54 (80.6) 20 (27) 0.007
Elevated white
blood cell*
60 (89.6) 22 (61.1) 0.001
Local complications* 1 (1.5) 5 (13.9) 0.01
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As the mortality rate from acute cholecystitis is not high,
hospital stay may be better in verifying the prognostic
factors of patients with this disease. The severity grading of
the Tokyo guidelines could stratify our patients by different
lengths of hospital stay. However, our results demonstrated
that the associated comorbidities of the patients also had
an impact on the length of hospital stay. In our study, the
surgeons selected the most suitable patients who had less
comorbidity for cholecystectomy, and therefore these pa-
tients had the shortest hospital stay. The patients who were
unsuitable for surgery and required percutaneous chol-
ecystostomy usually had more severe local complications,
and thus these patients had the longest hospital stay. By
applying multivariate linear regression, we found that the
severity of disease (Grade III cholecystitis) and comorbid-
ities (higher Charlson’s Comorbidity Score) significantly
influenced the length of hospital stay.
Only 74 patients (71.8%) fulfilled the diagnostic criteria
of the Tokyo guidelines. This is relatively low in comparison
with other studies [4], which may be attributed to some
patients who had vague signs of systemic inflammation and
equivocal imaging findings of acute cholecystitis. Similarly,
Lee et al. [8] also reported that the proportion of patients
with fever was 44.3%, with an elevated CRP of 53.2%, and
with an elevated WBC count of 55.3% in their case series.
For the other 29 patients that did not fulfill the diagnostic
criteria of the Tokyo guidelines, the diagnosis of acute
cholecystitis was confirmed by either surgical pathological
findings or dirty bile drainage on cholecystostomy.
Lee et al. [5] retrospectively studied their case series
and reported that there were no differences between
complications and mortality between patients who were
compatible and not compatible with the Tokyo guidelines.
They concluded that there was no significant benefit ach-
ieved by applying the Tokyo guidelines to clinical practice.Table 4 Complication rate according to Tokyo grading
and treatment modality.
Cholecystostomy Surgery Total*
Tokyo Grade I 2/13 (15.4) 1/18 (5.6) 3/31 (9.7)
Tokyo Grade II 3/9 (33.3) 4/16 (25.0) 7/25 (28.0)
Tokyo Grade III 9/18 (50.0) 0/2 (0) 9/20 (45.0)
Total* 14/40 (35.0) 5/36 (13.9) 19/76 (25.0)
Data are presented as n (%).
*p < 0.05 by Pearson’s Chi-square test.As seen from the studies of Lee et al. [5] and our study, the
mortality rate of acute cholecystitis is not high, ranging
from 2% to 3%. Other studies similarly showed low mortal-
ity, even in elderly or non-operable cases [9,10]. Thus,
utilizing the mortality rate may be less practical than using
other parameters such as hospital stay or complication rate
to assess the outcome of different treatment methods. Our
study showed that both the complication rate and the
length of hospital stay increased along with the severity of
Tokyo grading, which thereby validated the usefulness of
Tokyo grading in stratifying patients of different severity.
The Tokyo guidelines classify patients with organ/sys-
temic dysfunctions as Grade III, and patients with local
severe inflammation as Grade II. Our therapeutic decisions
were mostly compatible with the recommendations of the
Tokyo guidelines in the Grade III patients, and only two of
our patients who had systemic complications underwent an
early cholecystectomy. However, discrepancies were noted
in our Grade I and Grade II patients in that only one third of
the Grade I patients and nearly half of the Grade II patients
underwent cholecystectomy. It seems that in addition to
the disease severity, the surgeons had other concerns whenCharlson’s Comorbidity
Score**
1.78  1.69 0.47  0.70 <0.001
Hospital stay (d)** 10.5  6.8 8.2  3.9 0.032
Data are presented as n (%).
*p < 0.05 by Pearson’s Chi-square test.
**p < 0.05 by Student t test.
BMIZ body mass index; CRPZ C-reactive protein; RUQZ right
upper quadrant.
a The other characteristics were not listed because those
were not different between groups, including Murphy’s sign,
fever, positive imaging finding, onset > 72 hours, RUQ tender-
ness mass, white blood cell > 18,000/mL, cardiovascular,
neurologic, pulmonary, hepatic, and hematologic dysfunction.
Table 6 Univariate and multivariate linear regression of predictors for days of hospital stay.
Univariate p Multivariate p
Ratio of hospital stay (95% CI) Ratio of hospital stay (95% CI)
Age (per y) 0.089 (0.011e0.167) 0.025 0.002 (0.061e0.066) 0.943
Sex (female to male) 2.154 (0.237e4.524) 0.075 0.799 (1.006e2.603) 0.382
Severity from Grade II to I 1.902 (0.485e4.289) 0.117 0.460 (1.783e2.703) 0.685
Severity from Grade III to I* 7.875 (5.285e10.464) <0.001 2.901 (0.122e5.768) 0.041
Fever 1.254 (1.404e3.913) 0.351
HR (1/min) 0.074 (0.010e0.139) 0.024 0.024 (0.030e0.079) 0.376
Elevated CRP 1.740 (0.998e4.478) 0.210
Charlson’s Comorbidity Score
(per point increase)*
1.943 (1.274e2.611) <0.001 1.157 (0.407e1.907) 0.003
Cholecystostomy to antibiotics 5.565 (2.811e8.318) <0.001 1.819 (0.581e4.219) 0.136
Surgery to antibiotics 1.009 (e1.805e3.823) 0.478 1.659 (0.752e4.069) 0.175
Complication* 8.565 (6.012e11.119) <0.001 5.860 (3.375e8.346) <0.001
*p < 0.05 by multivariate linear regression.
CI Z confidence interval; CRP Z C-reactive protein.
464 W.-C. Cheng et al.selecting Grade I and Grade II patients for cholecystectomy.
Despite the fact that the Tokyo guidelines adopted six kinds
of organ dysfunction as Grade III severity, patients who
have a history of comorbidity, but who are not complicated
with organ dysfunction on presentation, will be graded as I
or II. These patients, however, are prone to develop organ
dysfunction and cannot be identified by Tokyo grading. As
shown in our study, there were more patients with severe
inflammation (elevated CRP and WBC) and higher Charl-
son’s Comorbidity Score in the nonsurgical group than in the
surgical group. Comorbidity which may complicate the
postoperative course should be another concern when
surgeons choose patients for cholecystectomy.
Among the patients who did not undergo surgery and
responded poorly to antibiotics, percutaneous chol-
ecystostomy is considered to be the treatment of choice
[11e15]. However, percutaneous cholecystostomy carries a
higher complication rate compared to surgery [9,10]. The
occurrence of complications, therefore, inevitably in-
creases the length of hospital stay. In our study, regardless
of the severity grade of the Tokyo guidelines, patients who
received percutaneous cholecystostomy had the longest
hospital stay. Abi-Haidar et al. [10] reported that patients
with a Charlson’s Comorbidity Score > 4 were more likely to
receive percutaneous cholecystostomy than cholecystec-
tomy. The presence of poor general condition prior to the
occurrence of acute cholecystitis per se may thereby
contribute to worse clinical outcomes [16,17]. As shown in
our study, the impact of treatment modality on length of
hospital stay was eliminated by multivariate analysis. Our
findings are consistent with the report of McGillicuddy et al.
[9], suggesting that the longer hospital stay of the nonsur-
gical group was due to the surgeons selecting the fittest
cases for surgery rather than the treatment method.
As no prospective study has assessed the factors that can
predict the outcomes of patients undergoing different
treatment methods, current studies may only indicate un-
favorable factors for surgery according to the expertise of
the surgeons. However, we believe that these “unfavorable
factors” are risk factors for a poor outcome, as evidenced
by the patients who underwent cholecystectomy having a
shorter hospital stay.In summary, surgeons usually select the patients with
lower Tokyo severity grading and lower Charlson’s Comor-
bidity Score for early cholecystectomy, and they had a
shorter hospital stay. The other patients will be treated by
staging operations and conservative medical treatment.
Both Tokyo severity grading and the patient’s comorbidities
(i.e., Charlson’s Comorbidity Score) have an impact on
therapeutic decision making of surgeons and also the clin-
ical outcomes of patients with acute cholecystitis.References
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